Q-omics provides the consensus-scored FBXO3 profile across patient tissues and cancer cell-line models. FBXO3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXO3 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FBXO3 RNA expression shows 21,158 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where FBXO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO3 survival associations across molecular data types. FBXO3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO3 RNA expression–survival associations across cancer types. High FBXO3 expression shows unfavorable associations in LUSC, KICH and ACC, but favorable associations in KIRC, BRCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXO3 RNA expression.
This table summarizes FBXO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO3 shows lower tumor expression in THCA, KICH, UCEC, COAD and LUAD and higher tumor expression in LIHC. The THCA box plot shows higher FBXO3 RNA expression in normal versus tumor tissue (log2 FC = −0.739, t-test p < 0.001).
This table shows molecular features associated with FBXO3 in patient tissues and cancer cell lines. In patient samples, FBXO3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
